ABC | Volume 115, Nº2, Agosto 2020

Carta ao Editor Fernandes et al. Os Riscos da Divulgação de Dados Científicos pela Mídia Arq Bras Cardiol. 2020; 115(2):278-280 Este é um artigo de acesso aberto distribuído sob os termos da licença de atribuição pelo Creative Commons 1. World Health Organization.(WHO) Coronavirus disease (COVID-19) Situation Report of the World Health Organization 2020.[Cited in 2020Apr12]. Available from: https://www.who.int/docs/default/coronavirus 2. MesquitaCT,OliveiraA,SeixasFvL,PaesA.Infodemia,FakeNewsandMedicine: ScienceandTheQuest forTrut. Int JCardiovascSci. .2020:aheadofprint. 3. Helms J, Tacquard C, Severac F,Leonard-Lorant Y, Ohana M, Delabranche X, et al. High risk of thrombosis in patients with severe SARS-CoV-2 infection: amulticenter prospective cohort study. Intensive CareMed. 2020. Doi:10.1007/s00134-020-06062-x 4. Dolhnikoff M, Duarte-Neto AN, de AlmeidaMonteiro RAFerraz da Silva LF, Oliveira EP, Saldiva PH, etal. Pathological evidence of pulmonary thrombotic phenomena in severe COVID-19. J ThrombHaemost. 2020;18(6):1517-9. 5. Zhang L, Yan X, FanQ, LiuH, LiuH, Liu Z, et al. D-dimer levels on admission topredict in-hospitalmortality inpatientswithCovid-19. JThrombHaemost. 2020; ahead print. 6. Gattinoni L, Coppola S, Cressoni M, Busana M, Rossi S, Chiumello D. Covid-19DoesNotLeadtoa“Typical”AcuteRespiratoryDistressSyndrome. Am J Respir Crit Care Med. 2020. 7. Paranjpe I, Fuster V, Lala A,Glicksberg BS, Levin MA, Charney AW, et al, et al. Association of Treatment Dose Anticoagulation with In-Hospital Survival Among Hospitalized Patients with COVID-19. J Am Coll Cardiol. 2020:S0735-1097(20)35218-9. 8. Atallah B, Mallah SI, AlMahmeed W. Anticoagulation in COVID-19. Eur Heart J Cardiovasc Pharmacother. 2020. 9. Bikdeli B, Madhavan MV, Jimenez D, et al. COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-up. J Am Coll Cardiol. 2020 Apr 30;pvaa-036. 10. Nascimento JHP, Gomes BFdO, Junior PnRdC, et al. COVID-19 and Hypercoagulable State: A New Therapeutic Perspective. Arq Bras Cardiol. 2020;114(5):829-33. 11. Gautret P, Lagier JC, Parola P, Huang VT, Meddeb L, Mailhe M, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents. 2020:105949. 12. Fernandes CJCS. Devemos abordar todos os pacientes com COVID-19 da mesma forma? J Bras Pneumol.2020;46(4):e20200218. Referências 280